Sinemet CR and Pregnancy

Sinemet CR and Pregnancy: An Overview

Sinemet^® CR (carbidopa-levodopa CR) is a prescription medication most often used to treat Parkinson's disease. Based on animal studies, Sinemet CR may not be safe for use during pregnancy, although the full risks to humans are not currently known.

 

Sinemet CR and Pregnancy Category C

The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans, but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.

 

When given to pregnant rats, short-acting Sinemet decreased the number of live pups born. When given to pregnant rabbits, short-acting Sinemet increased the risk of various birth defects. It is presumed that Sinemet CR would cause similar problems (compared to short-acting Sinemet).

 

It is important to keep in mind that animals do not always respond to medicines in the same way that humans do. Therefore, a pregnancy Category C medicine may be given to a pregnant woman if her healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child. Sinemet CR has not been adequately studied in humans, and there have only been a few cases in which women took Sinemet CR during pregnancy (as Parkinson's disease is rare in young women). In these few reported cases, Sinemet CR did not appear to cause any problems.